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The platelet-derived growth factor b receptor (PDGFRb) is known to activate many molecules involved in signal
transduction and has been a paradigm for receptor tyrosine kinase signaling for many years. We have sought to
determine the role of individual signaling components downstream of this receptor in vivo by analyzing an allelic
series of tyrosine–phenylalanine mutations that prevent binding of specific signal transduction components. Here we
show that the incidence of vascular smooth muscle cells/pericytes (v/p), a PDGFRb-dependent cell type, can be
correlated to the amount of receptor expressed and the number of activated signal transduction pathways. A decrease
in either receptor expression levels or disruption of multiple downstream signaling pathways lead to a significant
reduction in v/p. Conversely, loss of RasGAP binding leads to an increase in this same cell population, implicating a
potential role for this effector in attenuating the PDGFRb signal. The combined in vivo and biochemical data suggest
that the summation of pathways associated with the PDGFRb signal transduction determines the expansion of
developing v/p cells.
Introduction
Although signal transduction by receptor tyrosine kinases
(RTKs) has been studied extensively, the roles of individual
signaling proteins downstream of these receptors are a
matter of debate. Some studies have shown that disruption
of particular pathways leads to loss of speciﬁc cellular
functions (Valius and Kazlauskas 1993). Others have suggested
that it is the sum of the signals that results in the unique
cellular outcomes directed by each receptor (Fambrough et
al. 1999). Yet others have demonstrated that the interpreta-
tion of receptor signals is determined by the distinct cellular
history (Flores et al. 2000; Halfon et al. 2000; Xu et al. 2000).
Because many of these conclusions have been reached in
diverse cell types and through the analysis of different RTKs,
it is difﬁcult to determine whether results from one receptor
system can be used to generalize the functions of RTK
signaling.
Recently, several labs have dissected the roles of RTK
modular signaling components by generating point muta-
tions in cytoplasmic domains of the receptors in mice
(Partanen et al. 1998; Heuchel et al. 1999; Blume-Jensen et
al. 2000; Kissel et al. 2000; Tallquist et al. 2000; Klinghoffer et
al. 2001, 2002; Maina et al. 2001). These studies have revealed
a unique requirement for individual signaling components in
speciﬁc cell types (Partanen et al. 1998; Blume-Jensen et al.
2000; Kissel et al. 2000; Maina et al. 2001). In contrast, similar
experiments on platelet-derived growth factor receptor a
(PDGFRa) signaling mutants have demonstrated that phos-
phatidylinositol 39-kinase (PI3K) and Src family kinase (SFK)
signal transduction pathways play roles in oligodendrocyte
development (Klinghoffer et al. 2002). These experiments
suggest that requirements for signal transduction vary not
only by the receptor under consideration, but also by the cell
lineage that is receiving the signal.
The platelet-derived growth factor receptor b (PDGFRb)
has not only been studied physiologically, but also has been
the focus of intensive biochemical analysis. Upon ligand
binding, the PDGFRb dimerizes and is autophosphorylated
on as many as 13 cytoplasmic tyrosine residues. These
phosphorylated tyrosines become binding sites for SH2
domain-containing proteins that initiate a number of signal
transduction pathways (reviewed by Claesson-Welsh 1994;
Heldin et al. 1998). The pathways downstream of the PDGFRb
control multiple cellular functions, including proliferation,
migration, matrix deposition, and immediate early gene
induction (reviewed by Heldin and Westermark 1999;
Betsholtz et al. 2001). At least ten distinct SH2 domain-
containing proteins can bind the phosphorylated PDGFRb
and activate downstream signal transduction cascades. These
molecules include SFK (Kypta et al. 1990), PI3K (Kazlauskas
and Cooper 1990; Kundra et al. 1994; Wennstrom et al. 1994a,
1994b), Shc (Yokote et al. 1994), RasGAP (Kaplan et al. 1990;
Kazlauskas et al. 1990), signal transducers and activators of
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PLoS BIOLOGYtranscription (STATs) (Vignais et al. 1996), Grb2 (Arvidsson et
al. 1994), Grb7 (Yokote et al. 1996), SH2-containing phos-
photyrosine phosphatase (SHP-2, also known as SH-PTP2)
(Kazlauskas et al. 1993; Lechleider et al. 1993), phospholipase
Cc (PLCc) (Meisenhelder et al. 1989; Morrison et al. 1990),
and Nck (Nishimura et al. 1993). While multiple downstream
effects have been attributed to activation of these pathways,
their relative importance downstream of the PDGFRb has not
been determined in vivo.
We have concentrated our present analyses on signal
transduction by the PDGFRb. Previous studies using a null
allele of the receptor have demonstrated that PDGFRb signal
transduction is required for a subset of vascular smooth
muscle cells and pericytes (v/p) (Leve ´en et al. 1994; Soriano
1994). These cells are the mesenchymal support cells that
surround blood vessels (reviewed by Hungerford and Little
1999). Brain pericytes, kidney mesangial cells, retinal mural
cells, and limb and skin pericytes have all been recognized as
PDGFRb-dependent cells (Lindahl et al. 1997a, 1998; Hell-
stro ¨m et al. 1999; Enge et al. 2002). Studies have indicated that
the PDGFRb is likely to play a key role in the proliferation,
migration, or both of a progenitor population (Hellstro ¨me t
al. 1999). These results explain why defective PDGF signal
transduction results in a reduction of the v/p cell lineage and
ultimately in perinatal lethality due to vessel instability
(Hellstro ¨m et al. 2001).
To examine the roles of PI3K and PLCc downstream of the
PDGFRb, we have previously disrupted their binding sites in
the receptor’s cytoplasmic domain (Heuchel et al. 1999;
Tallquist et al. 2000). Surprisingly, no overt phenotypes were
detected in homozygous mutants lacking these two pathways,
and deﬁciencies were observed only when the animals were
challenged physiologically. To assess the roles of the remain-
ing signal transduction pathways, we have created a PDGFRb
allelic series in mice (Figure 1). We refer to this series as the F
series because it contains Y–F mutations at the known
phosphorylated tyrosine residues. Using v/p cell number as
a readout for PDGFRb signal transduction, we have deter-
mined that the level of receptor expressed as well as the sum
of signaling pathways induced by the PDGFRb determines the
number of v/p cells that form. These results provide an
example of RTK signal transduction quantitatively control-
ling cellular development.
Results
Generation of the Allelic Series
Previous studies of the PDGFRb have revealed an essential
role for this receptor in v/p development, but attempts to
identify essential biochemical signals thus far have demon-
strated that loss of certain signaling pathways only diminishes
PDGFRb-driven responses (Heuchel et al. 1999; Tallquist et al.
2000). To study key signaling pathways, we have generated an
allelic series of PDGFRb mutants. Figure 1 illustrates the
mutations that we have generated in the PDGFRb locus and
the signaling pathways that are disrupted by these mutations.
Each mutant will be referred to by the number of tyrosines
(Y) that have been mutated. For example, the mutation in the
RasGAP-binding site is the PDGFRb
F1/F1 or F1/F1 mutant. The
truncation mutation of the PDGFRb (b
T) was created by the
introduction of a frameshift and subsequent premature stop
codon downstream of the RasGAP-binding site. Figure 2
illustrates the targeting events that were used to generate the
series of mutants. The F1-, F2-, F3-, F5-, and b
T-targeted
mutations were generated by engineering Y–F, Y–I, or
frameshift mutations in the same targeting vector (Figure
2A). The F7 mutation was generated by targeting the F5
heterozygous embryonic stem (ES) cells (Figure 2B; see
Materials and Methods). Cells that contained all mutations
on the same allele, as determined by Southern blotting, were
used to generate the F7 line. All mutant mice were viable and
fertile as homozygotes except the truncation allele, b
T, which
lacks the second half of the kinase domain and the SHP-2-
and PLCc-binding sites. Based on a similar mutation in the
PDGFRb, we assume that this receptor is kinase deﬁcient and
incapable of inducing DNA synthesis, but it still should bind
ligand and undergo receptor downregulation (Escobedo et al.
1988). Embryos homozygous for the b
T allele die perinatally
with a phenotype identical to that of the PDGFRb null
embryos. E18 embryos exhibit edema and hemorrhaging in
multiple tissues, including the kidney, brain, and skin (data
not shown). These results suggest that PDGFRb kinase activity
is required for v/p development and that the receptor cannot
function in the absence of kinase activity, unlike another
RTK, vascular endothelial cell growth factor receptor 1
(Hiratsuka et al. 1998).
Identification of V/P Cells
We examined the blood vessels of F series homozygous
mice by histology and detected no gross abnormalities (data
not shown). To obtain a more global perspective of v/p cell
populations, we introduced the XlacZ4 transgenic marker
into our F series mutant mice. The XlacZ4 transgenic mouse
expresses nuclear b-galactosidase in certain populations of
differentiated, nonproliferating v/p cells in the embryo and
the adult (Tidhar et al. 2001). As described below, using this
marker in adult animals, we identiﬁed vascular defects in the
Figure 1. PDGFRb Allelic Series
This ﬁgure depicts the mutant alleles generated in the mouse
PDGFRb genomic locus. X represents a mutation in the tyrosine-
binding site(s) for a particular signal transduction molecule. The F7
allele contains a disruption in one SFK-binding site because loss of
both sites results in diminished kinase activity (Mori et al. 1993). The
truncation allele (b
T) was created by deletion and subsequent
frameshift that results in a stop codon 32 amino acids past the
RasGAP-binding site.
DOI: 10.1371/journal.pbio.0000052.g001
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PDGFRb Signaling and VSMC DevelopmentF5 and F7 mice in the tissues of the eyes, hearts, and brains
(see Figures 7, 8, and 9; data not shown). This observation
suggests that both the F5 and F7 alleles function suboptimally
in tissues known to require PDGFRb signal transduction
(Lindahl et al. 1997a; Hellstro ¨m et al. 1999; Enge et al. 2002).
Although both of these mutations cause notable phenotypes
in some v/p populations, we have not observed pathologies in
all populations of PDGFRb-dependent v/p cells. V/p cell
populations with no overt phenotype in the F5 and F7 mice
include the kidney mesangial cells and pericytes in the skin
and skeletal muscle (data not shown). We have observed a
modest decrease in the number of nuclei present in F5/F5 and
F5/  kidney glomeruli, but have not detected glomeruloscle-
rosis with Masson trichrome stain (data not shown). The lack
of any pathological phenotype in these tissues suggests either
that the reduction in v/p cells is less severe than in the case of
the PDGFRb null mice, that the PDGFRa may be coexpressed
in these same tissues, or that these tissues can function
adequately even with reduced v/p cell numbers.
Because some populations of v/p cells appear to be more
dependent on PDGFRb signal transduction than others, we
reasoned that the PDGFRa might be coexpressed in the less-
affected v/p populations. Although PDGFRa has been
reported in a variety of mesenchymal cell lineages (Schatte-
man et al. 1992; Lindahl et al. 1997b; Takakura et al. 1997;
Zhang et al. 1998; Karlsson et al. 2000), we wanted to
determine whether any v/p populations express the PDGFRa
or whether it may be upregulated in any of the F series mice.
We crossed the PDGFRa
GFP line of mouse, which expresses a
nuclear-localized green ﬂuorescent protein (GFP) under the
control of the PDGFRa promoter (Hamilton et al. 2003), with
the F5 mutant mice and compared the GFP expression
pattern to the pattern of v/p cells in the kidney, eye, and brain
(Figure 3; data not shown). We have used three independent
markers to designate v/p cells: smooth muscle actin a (aSMA),
desmin, and the XlacZ4 transgene. Although PDGFRa-
expressing cells are found in the same tissues as v/p cell
markers, there is no overlapping expression of GFP with any
Figure 2. Targeting Strategy and Southern Blot
(A) Targeting vector used to create F5 mutant allele. Two exons contain all ﬁve mutated tyrosines.
(B) Targeting vector containing mutations in 59 exons used to generate the F7 mutant allele.
(C) Wild-type allele.
(D) Targeted allele with PGK–neo removal. Restriction enzyme abbreviations: Sp, SpeI; A, Asp718; S, SacI; RV, EcoRV; H, HindIII; X, XhoI; and RI,
EcoRI. Green boxes indicate probes used in Southern blotting for F7-targeted ES cells. The blue arrow indicates the exon where point mutation
causes frameshift in truncation mutation. Black boxes indicate wild-type exons. Red boxes indicate exons containing targeted mutations.
Restriction enzymes in red indicate sites introduced by mutagenesis to verify proper homologous recombination by Southern blotting. Circles
denote FRT sites. Triangles denote loxP sites.
(E) Southern blot results from various ES cell lines. SpeI digest using P1 probe. Blot with P2 probe gave expected results (data not shown). Lanes 1
and 3, F5 allele targeted. Lanes 2 and 4, wild-type allele targeted. Lanes 5 and 7, F5 mutant ES cells after and before Cre activity, respectively.
Lane 6, wild-type ES cell clone.
DOI: 10.1371/journal.pbio.0000052.g002
PLoS Biology | http://biology.plosjournals.org Volume 1 | Issue 2 | Page 290
PDGFRb Signaling and VSMC Developmentof the v/p cell markers in the arteries or veins in the vessels of
the eye and brain. PDGFRa-expressing cells are also absent
from the larger vessels of the kidney, but a population of
GFP
þ cells is detected within the kidney glomerulus (Figure
3A). These may be either kidney mesangial cells or vascular
adventitial ﬁbroblasts. Both are populations of cells that are
known to express the PDGFRa (Seifert et al. 1998). These data
indicate that PDGFRa is not expressed or upregulated in two
of the most affected tissues of the mutant mice, the eye and
the brain, but could be functioning as a surrogate coreceptor
with the PDGFRb.
V/P Development
To determine whether the reduction in v/p was caused by a
gradual loss or a developmental defect, we examined pericyte
populations in wild-type and mutant embryos. The XlacZ4
mouse marker can be used to identify speciﬁc v/p cell
populations as early as E12.5. We chose to observe pericytes
at E14.5 because at this timepoint v/p are abundant in wild-
type animals in several tissues, including the developing
spinal cord and intercostal vasculature. Figure 4 demon-
strates whole-mount visualization of the v/p cell populations
in E14.5 wild-type embryos and the most severe F series
mutant embryo (F7/ ). After examining several litters of F
series mutant embryos bearing the XlacZ4 marker, it was clear
that the entire panel of F series homozygous mutant embryos
could be distinguished from wild-type embryos simply by the
degree that blood vessels had acquired v/p (data not shown).
To obtain a quantitative view of these results, we chose to
focus on the spinal cord pericyte population. These cells
begin to form at E10.5 in a rostral-to-caudal fashion in the
embryo and require PDGFRb signals for development
(Leve ´en et al. 1994). Cross-sections through the developing
spinal cord (neural tube) provide a relatively uniform area for
quantitation. We can consistently identify a particular
maturation stage of the developing vasculature based on its
axial level within the embryo, and the pericytes can often be
found as isolated cells (Figure 5). Using the entire panel of
PDGFRb mutant mice, we compared pericyte numbers
between the different F series mutants (Figures 5 and 6). In
all mutants examined, with the exception of the F1 mutation,
we observed a decreased incidence of pericytes when
compared to the wild-type embryos. The reduction in
pericyte numbers ranged from 42% to 77%. This reduction
was present at the more mature axial level of the heart as well
as at the axial level of the kidney.
The F7/F7 mutant embryos are the only embryos that
exhibited a difference between the number of pericytes at the
heart level versus the number at the level of the kidney. All
other mutants demonstrated similar numbers at both levels,
indicating that pericyte development is disrupted and does
not reach homeostasis as the tissue matures. Because the F7 is
the most severely affected allele, it is possible that the
difference between the heart and kidney levels is due to a
developmental delay in v/p formation. Pericyte development
may still be proceeding at the level of the kidney in these
embryos. At the more mature level of the heart, the F7/F7
pericyte populations have reached a steady-state level and
resemble v/p numbers more similar to those observed in the
F5/F5 embryos.
Previously, chimeric analysis had demonstrated that
PDGFRb heterozygous cells do not contribute extensively to
the smooth muscle cell compartment, suggesting that
heterozygous cells may have reduced v/p developmental
potential (Crosby et al. 1998). To ﬁnd out whether receptor
levels had any impact on v/p cells in our system, we crossed
animals bearing the PDGFRb null allele to our mutant series
(Figures 5B and 6B). We observed an even further reduction
in pericyte levels, resulting in a 70%–92% decrease in
pericytes when compared to wild-type embryos. Interestingly,
even the PDGFRb
þ/  embryos, which exhibit a approximately
50% reduction in PDGFRb messenger RNA (Soriano 1994),
demonstrate a nearly 40% decrease in pericytes. This result
Figure 3. Tissue Localization of V/P Cell Markers and PDGFRa Expression
Tissue preparations from P21 PDGFRa
GFP/þ;PDGFRb
F5/F5 mutant
mouse. Immunoﬂuorescence was used to detect aSMA (A and B),
desmin (C), b-galactosidase (D), and GFP expression for PDGFRa (A–
D). (A) Kidney (200 lm vibratome section). The arrow indicates
glomerulus. The asterisk indicates an arteriole. (B–D) Retina (whole-
mount preparation). Arrowheads point to b-galactosidase-positive
nuclei.
DOI: 10.1371/journal.pbio.0000052.g003
Figure 4. Reduction in V/P Cells in the Thoracic Region of E14.5 Embryos
Ventral view of E14.5 wild-type and F7/  littermates with the XlacZ4
mouse marker background. b-Galactosidase-positive nuclei represent
v/p cells. Th, thymus.
DOI: 10.1371/journal.pbio.0000052.g004
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pericytes. Another observation from this data is that even the
F7/  embryos can induce cell development at levels greater
than the null. In fact, the F7/  animals survive, whereas the
PDGFRb nulls do not. This is a rather surprising result given
that most of the downstream signal transduction molecules
that directly interact with the receptor have been dissociated.
While most of the F series alleles demonstrate a decrease in
v/p cells, the F1 allele results in an apparent increase in spinal
cord pericytes. Although the increase is most pronounced
when we compare the F1 hemizygote to the PDGFRb
heterozygote (Figure 6), an increase is also observed when
comparing F1/F1 embryos and wild-type embryos. In fact, the
level of pericytes in the F1/  embryos is very similar to those
in the wild-type. These data demonstrate two interesting
ﬁndings. One is that RasGAP may play a role in PDGFRb
signal attenuation and that loss of this pathway results in
increased PDGFRb signals. The second is that v/p numbers
may not be tightly controlled and that PDGFRb signaling can
result in more cells.
To determine whether the signaling pathways affected
other v/p populations in the same manner, we have examined
the v/p population in the retina. It has been shown previously
that PDGFB and PDGFRb signaling controls pericyte devel-
opment in the eye (Benjamin et al. 1998; Klinghoffer et al.
2001; Enge et al. 2002). Adult mice transheterozygous for one
null allele and one F5 or F7 allele exhibited severe eye defects.
These defects were ﬁrst observed as an opacity and sometimes
as visible hemorrhage in the eye (Figure 7A), as previously
described for PDGFRb and PDGFB signaling mutants
(Klinghoffer et al. 2001; Enge et al. 2002). The F5 and F7
hemizygous mutant mice possessed fewer discontinuous
blood vessels and overgrowth of retinal cells. This phenotype
occurred with 100% penetrance, but with variable severity
(Figure 7C), and was detectable sometimes as early as 4 d after
birth. The presence of a pathological condition suggests that
the F5 and F7 alleles have compromised receptor function
when compared to the wild-type, F1, F2, and F3 alleles and
demonstrates that retinal pericytes are also dependent on the
PDGFRb signaling pathways that we have disrupted.
To examine the retinal pericytes in the entire F series, we
again used mice bearing the XlacZ4 transgene. At 4 wk of age
the retinal vasculature is mature and can be isolated from the
lens and pigmented epithelium for visualization. Figure 8
illustrates that homozygotes for the F1, F2, and F3 mutant
alleles are indistinguishable from wild-type eyes; however, F5/
F5 and F7/F7 eyes exhibit reduced numbers of pericytes. Even
without the ability to quantitate these differences, it is clear
that the PDGFRb
þ/ , F5/F5, F7/F7, F5/ , and F7/  mutant
retinas have a reduction in v/p when compared to wild-type
eyes, reinforcing the requirement for multiple PDGFRb
signal transduction pathways in v/p development.
A ﬁnal tissue where we have examined v/p formation is the
heart. F2 and F3 homozygotes and transheterozygotes were
indistinguishable from wild-type and heterozygous hearts,
respectively. Consistent with our observations in the eye and
the nervous system, the F5 and F7 mutant alleles display
abnormalities in the vascular coating of their coronary
Figure 5. Pericytes within the E14.5 Nervous System of F Series Mutant Embryos
(A) Representative sections through neural tubes of embryos from the homozygous F allelic series. (B) Representative sections of embryos from
the hemizygous allelic series (F series mutant with one copy of the null allele). Sections are from the rostral level between the heart and kidney.
Pericytes are visualized by nuclear-localized b-galactosidase staining in cells committed to the v/p lineage. Sections are 7 lm.
DOI: 10.1371/journal.pbio.0000052.g005
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mice often exhibited a variety of heart abnormalities,
including enlarged ventricles, increased heart:body mass
ratio, dilated atria, and ﬁbrosis (data not shown). In contrast,
the F1/þmice appeared to have more extensive v/p coating on
their coronary arteries (Figure 9). In agreement with the data
from the nervous system and the eye, the F5 and F7 mutant
alleles have a signiﬁcant reduction in v/p cells.
Taken together, these results demonstrate several impor-
tant ﬁndings for PDGFRb signal transduction. First, the
number of pericytes formed directly correlates with the
number of signaling pathways transducing PDGFRb activity.
Second, a reduction in pericytes is observed even when only
the amount of receptor is affected. Finally, although SH2
domain-containing proteins impact v/p numbers, the intrin-
sic kinase activity of the receptor may play a role in
transmitting the PDGFRb signal because the truncation
mutation does not exhibit any rescue of v/p development,
while the F7 mutant allele that transmits primarily through
kinase activity (owing to loss of the SH2 domain-containing
protein-binding sites) still supports v/p development sufﬁ-
cient for viability.
Downstream Signal Transduction
Because F2, F3, and F5 mutant receptors have been
previously studied biochemically (Valius and Kazlauskas
1993; Heuchel et al. 1999; Tallquist et al. 2000), we have
focused our biochemical analysis on the F1 and F7 mutant
receptors’ signal transduction to verify the effects of these
particular mutations on downstream signal transduction
cascades. We have used mouse embryo ﬁbroblasts (MEFs)
for these analyses. All lines of MEFs that we generated
expressed the PDGFRb at similar levels (Figure 10D) as well as
the PDGFRa (data not shown). To avoid stimulation of the
PDGFRa by PDGFBB, we downregulated PDGFRa surface
expression by pretreatment with PDGFAA 2 h before
PDGFBB stimulation. In all cell lines examined, we observed
an increase in tyrosine phosphorylation in response to ligand
(Figure 10A). The most evident phosphorylated bands are
around 200 kd, which are likely to be the PDGFRa and
PDGFRb. Although we have mutated seven of the 13
tyrosines, a signiﬁcant amount of phosphorylation is ob-
served in all cell lines, albeit at lower levels in the F7/  cell
Figure 6. Quantitation of Pericytes in Nervous System
b-Galactosidase-positive nuclei were counted within the neural tube. Each datapoint represents a mean of seven to ten sections from a single
embryo. Data were gathered at two rostral levels in each embryo. The genotypes are ordered by the predicted strength of the signal, depending
on the number of copies of the receptor being expressed and the signal transduction pathways remaining downstream of the receptor. A two-
tailed Student’s t-test was performed comparing the number of spinal cord perictyes in mutants to those in wild-type, and all homozygous
mutants and hemizygous mutant values were statistically different (p , 0.005) from wild-type values. The F1/ was also statistically different from
the PDGFRb
þ/  (p , 0.001).
DOI: 10.1371/journal.pbio.0000052.g006
Figure 7. Eye Defects in F5/  Mice
(A) Eyes from a P4 F5/  mouse demonstrating severe hemorrhaging.
(B and C) H/E-stained sagittal sections through eyes of wild-type and
F5/  3-mo-old mice, respectively. The absence of the lens of the F5/ 
eye is a histological defect and not a phenotype of the F5/  eye. L,
lens; R, retina.
DOI: 10.1371/journal.pbio.0000052.g007
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tyrosine blot, the phosphorylated protein detected at 200 kd
is likely cytoplasmic PDGFRa, as it is reduced in F7 cells after
downregulation of the PDGFRa.
Because we have disrupted only one of the potential Src-
binding sites, we examined the level of Src activation
downstream of our F7 cell line (Figure 10B). Upon PDGFBB
addition, there was an increase in the amount of Src
phosphorylated on tyrosine 418 (a site whose phosphoryla-
tion is required for full catalytic activity; Johnson et al. 1996).
In contrast, in the F7/F7 MEFs, we did not observe any
increase in Src activation. These results are in agreement with
other reports that demonstrate that a mutation at amino acid
578 of the PDGFRb is sufﬁcient for reducing the level of Src
binding and activation (Mori et al. 1993; Twamley et al. 1993;
Vaillancourt et al. 1995; Fanger et al. 1997).
Two potential downstream targets of PDGFRb activation
are activation of extracellular signal-related kinases 1 and 2
(ERK1/2) and AKT (Franke et al. 1995). As expected,
phosphorylation of ERK1/2 and AKT is reduced or absent
in the F7 homozygous and hemizygous mutant cell lines, but
cells expressing at least one copy of the wild-type receptor are
capable of inducing the activation of these downstream
molecules (Figure 10C). These data demonstrate that loss of
seven tyrosine residues on the PDGFRb results in a severe loss
of downstream signal transduction. In contrast, cells bearing
even just one copy of the F1 receptor show increased
phosphorylation of ERK1/2. These data are in concordance
with the in vivo data, which show that lack of the RasGAP-
binding site on the receptor results in an increase in the
downstream signaling events and a subsequent increase in v/
p. Therefore, the F1 mutant receptor has increased activity
while the F7 receptors have decreased activation of these
same pathways, despite having apparently normal levels of
kinase activity.
Discussion
RTK signal transduction plays an important role in
directing many cellular activities. We have used an in vivo
system to analyze how cellular development relates to the
signaling pathways downstream of the PDGFRb. Examination
of the v/p population demonstrates a quantitative relation-
ship between the extent that signals are being transduced and
the number of v/p that form. Several other studies have
demonstrated that combinations of signal transduction
pathways may dictate cellular outcomes. Examples of these
are T cell development in the immune system and gradients
of morphogens in developmental systems (Heemskerk and
Figure 9. Vascular Smooth Muscle Cells of the Coronary Arteries
(Top) Whole-mount views of P21 hearts from littermates of the F5
alleles of mutant mice. Hearts were sliced coronally, and the ventral
surface was photographed. The F5/  heart was sliced disproportion-
ately and therefore appears to be smaller.
(Bottom) P28 hearts from wild-type and F1 littermates. Hearts were
sliced sagittally. Both the left and right views are shown.
DOI: 10.1371/journal.pbio.0000052.g009
Figure 8. V/P Populations in P28 Retinas
Whole-mount retinal preparations from wild-type and mutant eyes. Pigmented epithelium was removed for visualization of b-galactosidase.
Note F7/F7 and F7/ had extensive thickening of the retinal layers that resulted in a contraction of the entire retina and apparent reduction in
size. The far right panel shows a close-up of the artery and vein of three homozygous eyes.
DOI: 10.1371/journal.pbio.0000052.g008
PLoS Biology | http://biology.plosjournals.org Volume 1 | Issue 2 | Page 294
PDGFRb Signaling and VSMC DevelopmentDiNardo 1994; Nellen et al. 1996; Zecca et al. 1996; Ferrell and
Machleder 1998; Gong et al. 2001).
In our system, the signal can be affected in two ways. The
ﬁrst is by the amount of receptor expressed at the cell surface.
V/p numbers are signiﬁcantly lower in PDGFRb
þ/  embryos
when compared to wild-type controls. In this situation there
is a decrease in overall signal, but no speciﬁc, directly
associated pathway is disrupted. This demonstrates a quanti-
tative role for receptor activity. The second inﬂuence on
PDGFRb signal transmission is by the number of associated
SH2 domain-containing proteins. Loss of even a single
pathway results in reduction of v/p, and as the number of
disrupted pathways increases, there is a concomitant decrease
in v/p. There is no signiﬁcant difference between the F2 and
the F3 mutant alleles, but there is a noticeable difference
when the number of mutations is further increased. These
signaling differences as illustrated by v/p number and the
presence of vascular pathologies can be categorized in the
mutant alleles by the following hierarchy: F1 . wild-type .
F2 ¼ F3 . F5 . F7 . null. In addition, hemizygotes show an
even further reduction in v/p when compared to the F series
homozygotes. This suggests that speciﬁc effector pathways
may play more of a role in ﬁne-tuning PDGFRb signals.
In total, our results demonstrate that PDGFRb signal
transduction is regulated not only by direct binding of signal
transduction molecules, but also by receptor expression
levels, possibly reﬂecting inherent kinase activity. In addition,
no particular signaling pathway that we have analyzed is
absolutely required for transmission of PDGFRb signals,
because even the F7 allele has a phenotype less severe than
the null. In support of the observation that receptor levels
and kinase activity may have a direct role in signal trans-
duction, we have observed that a chimeric PDGFR that has
the extracellular domain of the PDGFRb but the intracellular
domain of the PDGFRa exhibits a more severe phenotype
than the F5 allele (Klinghoffer et al. 2001). This chimeric
receptor can signal through all of the same downstream
components as the PDGFRb except for RasGAP, suggesting
that the more severe vascular defects in these chimeric
receptor mice may be due to reduced kinase activity and/or
expression levels of the chimeric receptor.
The PDGFRb’s signaling pathways appears to dictate the
absolute numbers of v/p that form, but how the individual
pathways contribute to this phenotype remains to be tested.
In fact, very little difference in numbers of v/p is observed
between the F2 and the F3 mutants, suggesting that PLCc
signals may be somehow redundant with or dependent on the
PI3K pathway. In contrast, loss of additional pathways leads
to an incremental loss of v/p. The difference between the F3
and the F5 mutations is the ability to bind SHP-2 and
RasGAP, and it has been proposed that both of these
molecules play roles in downregulating the PDGFRb signal
(Klinghoffer and Kazlauskas 1995; Ekman et al. 1999). Our
results demonstrate that loss of these signaling pathways is
detrimental to PDGFRb signal transduction and that both
may have positive and negative inﬂuences on receptor
activity.
There are several potential ways that loss of these signaling
pathways leads to v/p reduction. One mechanism would be
that each pathway contributes to a speciﬁc cellular outcome.
For example, SFK’s predominant role could be to promote
proliferation (Roche et al. 1995; Hansen et al. 1996), whereas
PI3K activity could be more important for migration (Kundra
et al. 1994; Wennstrom et al. 1994b). Therefore, the combined
loss of these pathways results in a net reduction in v/p, albeit
for entirely different cellular reasons. A second scenario
would be that all pathways lead to a single or few speciﬁc
cellular conclusions. Thus, loss of any one pathway only
reduces the outcome but does not ablate it. Evidence from
immediate-early gene expression analysis suggests that this
mechanism may occur (Fambrough et al. 1999), although this
possibility does not require that all pathways contribute
equally. Last, some pathways may play a primary role
downstream of the receptor, while others may be more
secondary.
Figure 10. Biochemistry of MEFs from F7 and F1 Mice
(A) Whole-cell lysates were generated from MEFs that were
unstimulated or stimulated with PDGFAA and/or PDGFBB alone,
100 ng/ml and 30 ng/ml, respectively. Lysates were then subjected to
SDS–PAGE and Western blotting accomplished with the anti-
phosphotyrosine antibody (4G10).
(B) Immunoprecipitation of tyrosine-phosphorylated proteins from
wild-type and the F7 series of mutant MEFs. The precipitates were
then run on SDS–PAGE, and a Western blot was performed using
anti-Src [pY
418] antibody and anti-PDGFRb 97A.
(C) Whole-cell lysates from unstimulated or stimulated MEFs. Lysates
were then subjected to SDS–PAGE and Western blotting accom-
plished with the indicated phosphorylated-speciﬁc antibodies. Blots
were stripped and blotted with antibodies to the corresponding
unphosphorylated proteins to demonstrate protein loading. Data are
representative of multiple experiments from at least two indepen-
dently derived cell lines.
(D) Western blots of whole-cell lysates from 5 310
4 cells per lane
blotted with antibodies to PDGFRb (06-498) and ERK as a loading
control.
DOI: 10.1371/journal.pbio.0000052.g010
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while the other pathways may be less signiﬁcant. The F2/F2
mutant mice have a signiﬁcant reduction in v/p numbers
when compared to the wild-type and the heterozygous mice,
and additional mutations have less of an effect than PI3K on
v/p numbers. A similar situation has been observed with the
PDGFRa (Klinghoffer et al. 2002): the phenotype of mouse
embryos with loss of the PDGFRa–PI3K pathway was just as
severe as that of embryos expressing a PDGFRa F7 allele
(which is similar to the F7 allele of the PDGFRb). The
pathological difference observed between the F5 and F7
alleles versus all of the other mutations suggests that SHP-2,
SFK, Grb2, and RasGAP also impact pericyte development.
Assessing the importance of these pathways would require
generating additional alleles with different combinations of
mutant sites. The only signaling differences between the F3
mutation and the F5 mutation are the SHP-2 and RasGAP
pathways. This suggests that one or both of these pathways
promote PDGFRb signaling, in contrast to the F1 mutation,
which demonstrates that absence of RasGAP leads to a
potential increase of PDGFRb signaling. This apparent
contradiction may indicate that RasGAP plays both a positive
and a negative role in signal transduction or that SHP-2 may
have mainly a positive role in modulating this response.
Although we ﬁnd that overall loss of downstream pathways
attenuates receptor actions as demonstrated by v/p forma-
tion, it is surprising that the F7/F7 mice do not phenocopy the
null animals. The F7 allele possesses disruptions at seven of
the 13 known phosphorylated tyrosine residues. These
mutations should disrupt a majority of the signal relay
molecules downstream of the receptor. The remaining
tyrosines are capable of binding SFKs, STATs, and Grbs.
Based on several previous reports, disruption of Y578 affects
the majority of SFK binding (Mori et al. 1993; Twamley et al.
1993; Vaillancourt et al. 1995; Fanger et al. 1997), and we have
shown that SFKs do not become activated after stimulation of
the F7 receptor. As for the signaling roles of STAT and Grb2
downstream of the receptor, little direct function has been
demonstrated for these remaining effector molecules in
PDGF-induced cellular responses (Heldin et al. 1998). There-
fore, F7 signal transmission must use some other means than
direct binding by SH2 domain-containing proteins. The
receptor should still have full kinase activity, unlike the lethal
b
T mutation, which is lacking half of the kinase domain and
the SHP-2- and PLCc-binding sites. Possibly, the receptor is
phosphorylating molecules that are only transiently associ-
ated. Another possibility is that other receptors may function
as surrogates. The most likely surrogate is the PDGFRa, but
we have demonstrated that in several of the v/p cell
populations the PDGFRa is not expressed. Other candidate
molecules for such a mechanism are integrins, ephrins, and
the low-density lipoprotein receptor-related protein LRP
(Miyamoto et al. 1996; Schneller et al. 1997; Woodard et al.
1998; Boucher et al. 2002; Loukinova et al. 2002). Although
these proteins are known to cross-talk with the PDGFRb,i ti s
unclear whether they have the capability to substitute for the
PDGFRb’s own signaling components.
The F1 mutant allele is an interesting corollary to the F
mutant series. While all of the other mutations appear to have
a detrimental effect on PDGFRb signal transduction, the F1
mutation results in an apparent increase in PDGFRb activity
as determined by v/p incidence. These data are in agreement
with previous observations that RasGAP function decreases
the Ras/MAP kinase pathway activity and migration (Kundra
et al. 1994; Ekman et al. 1999). In addition, an add-back
mutation of the RasGAP-binding site induced a different
gene proﬁle from the PDGFRb immediate-early gene proﬁle
(Fambrough et al. 1999). This suggests that RasGAP may have
different signaling capabilities from the other PDGFRb signal
transduction components.
The mutant mice not only uncover the role of RTK signal
transduction in vivo, but they also reveal some interesting
information regarding v/p cell development. For example,
although v/p cell development is impaired when PDGFRb
signal transduction is disrupted, a basal level of cells forms, in
agreement with previous observations that propagation, not
initiation, of v/p cell development is directed by the PDGFRb
(Lindahl et al. 1997a; Hellstro ¨m et al. 1999). Even in the null
embryos, v/p cells can be found. It has been proposed that
PDGFRb signals are required for the expansion of v/p cells
(Lindahl et al. 1998). While this may be the case, it is curious
that in the F5 and F7 animals, the pericyte numbers never
reach wild-type levels, resulting in vascular pathologies.
There are two explanations for the observation that v/p
cells never reach wild-type levels. The ﬁrst is that there is
constant turnover in the v/p population and that the rate of
replacement in the mutant mice is below the rate of loss,
resulting in a net reduction in the v/p population. Evidence
against this mechanism is the failure to observe any
signiﬁcant proliferation in the adult wild-type animals under
normal conditions or signiﬁcant apoptosis in the mutant
panel of mice (data not shown). The second possibility is that
there is a speciﬁc window during development when v/p cells
can expand. After a speciﬁed time, v/p cell number expansion
could be limited, perhaps related to the ability of endothelial
cells to secrete the PDGF ligand (Benjamin et al. 1998).
Support for this model is the inability of nascent endothelial
tubes to recruit v/p cells in tumors (Abramsson et al. 2002).
The inability to develop sufﬁcient numbers of v/p cells also
appears to be recapitulated in the eye vasculature, suggesting
that the maturation of the vessel is more dependent on the
local environment than on the chronological age of the
embryo.
Our ﬁndings demonstrate that the combination of signal-
ing pathways downstream of PDGFRb determines the total
number of v/p cells. These can be modulated not only by the
amount of receptor expressed at the cell surface, but also by
the number of speciﬁc downstream signaling pathways
activated by the receptor. Whether these results are unique
to PDGFRb signal transduction in v/p cells or whether they




Point mutations that disrupt the designated signal transduction
pathways were generated by changing the tyrosine residue to
phenylalanine. The exception was Y1020, which was mutated to
encode an isoleucine, thus generating a unique restriction site that
facilitated identiﬁcation of homologous recombinants. Mouse mu-
tants F2 and F3 have been previously described (Heuchel et al. 1999;
Tallquist et al. 2000). The targeting vector for the F1, F5, and b
T
mutations utilized the same arms of homology as the F3 vector. The
exons containing the point mutations were introduced in the arms of
homology of the targeting vector by site-directed mutagenesis and
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homozygous mutant mice. The F7 mutation was generated by
creating a targeting vector that incorporated the 59 arm of the F5
targeting vector with 59 genomic sequences that included the exons
containing the Src- and Grb2-binding sites. Tyrosines 578 and 715
were mutated to phenylalanine to disrupt Src and Grb2 binding,
respectively. This targeting vector was transfected into F5 hetero-
zygous ES cells and screened for homologous recombination. The
truncation mutation possesses a frameshift at amino acid 780,
resulting in a premature stop codon after amino acid 801, 11 amino
acids downstream of the RasGAP-binding site. ES cell colonies were
screened initially by PCR, and positive clones were further veriﬁed by
Southern blot analysis for the correct recombination at the 59 and 39
arms. The PGK–neo cassettes were removed by crossing mice to
Meox2
Cre (Tallquist and Soriano 2000) and ROSA26
FlpeR (Farley et al.
2000) deleters.
The majority of analyses have been carried out on a mixed 129S43
C57BL/6 background, except where indicated. The XlacZ4 transgenic
mouse (Tidhar et al. 2001) was kindly provided by Moshe Shani and
crossed into the F series. We also crossed the F5 and wild-type mice to
the PDGFRa
GFP line (Hamilton et al. 2003).
Histology, Immunohistochemistry, and Pericyte
Quantitation
Embryos and tissues were processed and embedded for sectioning
according to standard protocol. We have not examined the
vasculature of all PDGFRb-dependent tissues in the F series mutant
animals. Those tissues not examined are lung, brown adipose tissue,
and the adrenal gland.
Immunohistochemistry. Kidneys were removed and ﬁxed for 20
min in 4% paraformaldehyde, 200 lm sections were then obtained by
vibratome sectioning, and immunoﬂuorescence was performed. For
eye immunohistochemistry, the pigmented epithelium was removed
from the mouse retinas and ﬁxed for 10 min in 4% paraformalde-
hyde. Retinas and kidney slices were then blocked and subjected to
immunohistochemistry for the indicated v/p marker. Antibodies were
b-galactosidase (55976; Cappel, Costa Mesa, California, United
States), aSMA (1A4; Sigma, St. Louis, Missouri, United States), and
desmin (D33; Dako Cytomation, Glostrup, Denmark). Photographs
were obtained on a Zeiss Axiophot microscope (Carl Zeiss Micro-
Imaging, Thornwood, New York, United States).
Pericyte quantitation. E14.5 embryos were divided into quarters at
the following levels: head–neck, neck–liver, liver–kidney, and kidney–
tail. Quarters were rinsed with PBS and ﬁxed for 20 min in 2%
formaldehyde, 0.2% glutaraldehyde. They were then washed three
times in PBS, stained overnight with X-Gal, transferred to PBS,
photographed, post-ﬁxed in 10% formalin, and then processed and
embedded. Sections (7 lm) were generated and X-Gal-positive nuclei
quantitated in the neural tube at the level of the heart and the kidney.
Seven to ten samples were counted for each level; the mean of these
data is represented in Figure 6. Pericytes surrounding the exterior of
the neural tube were excluded from the sample. Positive nuclei were
counted at 203 magniﬁcation and photographed at 103 magniﬁca-
tion on Zeiss Axiophot microscopes. Retinas were prepared in a
similar manner. The pigmented epithelium was removed prior to the
initial ﬁxation step, and the lens was not removed until after the ﬁnal
ﬁxation to maintain retina shape. Images were obtained on a Nikon
SMZ1000 with a Coolpix 900 camera (Nikon Corporation, Tokyo,
Japan).
Immunoprecipitation and Western Blotting
MEFs were generated from E9-d-old or E14.5-d-old embryos.
Embryos were isolated, decapitated, and eviscerated. The remaining
tissue was then treated with trypsin and plated. Cells were frozen
down at passages 2 and 3. Most experiments were completed on cells
at passages 3–6, except for the wild-type line, which was sponta-
neously immortalized.
Cells were plated at 1310
5 to 3310
5 cells per well and starved for
48 h. Receptor downregulation was achieved by treating starved cells
for 2 h with 100 ng/ml PDGFAA (R&D). Cells were then stimulated
with PDGFBB (R&D) for 5 min and lysed.
Immunoprecipitation and Western blotting were executed as
previously described (Tallquist et al. 2000). Antibodies were obtained
from the following sources: PDGFRb (06-498; Upstate Biotechnology,
Lake Placid, New York, United States); PDGFRa (sc-338; Santa Cruz
Biotechnology, Santa Cruz, California, United States); Akt (9272; Cell
Signaling Technology, Beverly, Massachusetts, United States); Phos-
pho-AKT (9271; Cell Signaling Technology); RasGAP (05-178; Upstate
Biotechnology); Grb2 (610111; BD Transduction Laboratories, San
Jose, California, United States); ERK1/2 (06-182; Upstate Biotechnol-
ogy); c-Src (SRC2 and sc-18; Santa Cruz Biotechnology); Phospho-Src
Y418 (44-660; Biosource International, Camarillo, California, United
States); Phospho-ERK1/2 (9101; Cell Signaling Technology); PLCc (05-
163; Upstate Biotechnology); SHP-2 (sc-280; Santa Cruz Biotechnol-
ogy); and phosphotyrosine (4G10) (05-321; Upstate Biotechnology).




The LocusLink ID numbers discussed in this paper are PDGFRa
(Locus ID 18595) and PDGFRb (Locus ID 18596).
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